Pulse Ox Company Masimo Accuses Apple of Delaying Legal Battle to Sell More Apple Watches

Back in January, medical device company Masimo levied a lawsuit against Apple, accusing the company of stealing trade secrets and improperly using Masimo inventions related to health monitoring in the Apple Watch.


Masimo is known for its pulse oximetry devices, and Apple just recently debuted the Apple Watch Series 6 with blood oxygen monitoring capabilities. Following the launch of the Series 6, Masimo has accused Apple of attempting to delay the legal proceedings in order to sell more watches and gain a more dominant share of the smart watch market.

As highlighted by Bloomberg, Apple has not officially responded to the original January lawsuit, instead filing requests to dismiss the trade secret part of the case and to have Masimo patents invalidated. Apple has asked the trial court to put the case on hold until the patent issue is resolved, which could take a significant amount of time.

Apple told the court that delaying the case until a patent review will narrow the issues and “reduce wasted resources.” With no hold, the first hearing on the case will take place in April 2021.

According to Masimo, the potential postponement would allow Apple to “seize on a critical window of opportunity to capture an emerging field,” using its “considerable resources and ecosystem” to capture market share with no regard for Masimo patent technology.

Masimo CEO Joe Kiani said in the filing that Masimo believes Apple’s customers see the Series 6 as a “medical product,” which can “harm consumers” and “reduce [Masimo’s] opportunities to sell truly clinical-grade products to consumers.”

Masimo accused Apple of stealing secret information by pretending to have a working relationship with Masimo and then poaching Masimo employees. Masimo also believes that Apple is infringing on 10 Masimo patents, and says that Apple relied on Masimo technology when